Maryam Oskoui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7680025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An update on the prevalence of cerebral palsy: a systematic review and metaâ€analysis. Developmental Medicine and Child Neurology, 2013, 55, 509-519.	2.1	1,056
2	An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscular Disorders, 2007, 17, 693-697.	0.6	245
3	Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology, 2012, 79, 1889-1897.	1.1	207
4	Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy. Neurology, 2016, 86, 465-472.	1.1	183
5	Clinically relevant copy number variations detected in cerebral palsy. Nature Communications, 2015, 6, 7949.	12.8	120
6	Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder. Neurology, 2020, 94, 392-404.	1.1	119
7	Practice guideline update summary: Acute treatment of migraine in children and adolescents. Neurology, 2019, 93, 487-499.	1.1	103
8	Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology, 2019, 93, 500-509.	1.1	91
9	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	10.2	89
10	Evidence in focus: Nusinersen use in spinal muscular atrophy. Neurology, 2018, 91, 923-933.	1.1	72
11	The Epidemiology of Cerebral Palsy: New Perspectives From a Canadian Registry. Seminars in Pediatric Neurology, 2013, 20, 60-64.	2.0	53
12	The Placenta in Neonatal Encephalopathy: A Case–Control Study. Journal of Pediatrics, 2018, 202, 77-85.e3.	1.8	53
13	Contribution of socioâ€economic status on the prevalence of cerebral palsy: a systematic search and review. Developmental Medicine and Child Neurology, 2014, 56, 1043-1051.	2.1	50
14	Spinal Muscular Atrophy. Neurotherapeutics, 2008, 5, 499-506.	4.4	49
15	Factors Predictive of Outcome in Childhood Epilepsy. Journal of Child Neurology, 2005, 20, 898-904.	1.4	44
16	Variation in cerebral palsy profile by socioâ€economic status. Developmental Medicine and Child Neurology, 2016, 58, 160-166.	2.1	39
17	A Population-Based Study of Communication Impairment in Cerebral Palsy. Journal of Child Neurology, 2015, 30, 277-284.	1.4	38
18	Prevalence Estimate of Cerebral Palsy in Northern Alberta: Births, 2008-2010. Canadian Journal of Neurological Sciences, 2017, 44, 366-374.	0.5	35

#	Article	IF	CITATIONS
19	Prevalence of sleep problems and sleep-related characteristics in preschool- and school-aged children with cerebral palsy. Sleep Medicine, 2018, 50, 1-6.	1.6	34
20	Chorioamnionitis and cerebral palsy: Lessons from a patient registry. European Journal of Paediatric Neurology, 2014, 18, 301-307.	1.6	32
21	Growing Up With Cerebral Palsy: Contemporary Challenges of Healthcare Transition. Canadian Journal of Neurological Sciences, 2012, 39, 23-25.	0.5	30
22	Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Headache, 2019, 59, 1144-1157.	3.9	28
23	Cerebral Palsy after Neonatal Encephalopathy: How Much Is Preventable?. Journal of Pediatrics, 2015, 167, 58-63.e1.	1.8	27
24	Physician driven variation in the care of children with spinal muscular atrophy type 1. Pediatric Pulmonology, 2017, 52, 662-668.	2.0	27
25	Ethics challenges of transition from paediatric to adult health care services for young adults with neurodevelopmental disabilities. Paediatrics and Child Health, 2014, 19, 65-68.	0.6	26
26	Frequent users of the pediatric emergency department. Canadian Journal of Emergency Medicine, 2018, 20, 401-408.	1.1	25
27	Practice guideline update summary: Acute treatment of migraine in children and adolescents. Headache, 2019, 59, 1158-1173.	3.9	25
28	International expert recommendations of clinical features to prompt referral for diagnostic assessment of cerebral palsy. Developmental Medicine and Child Neurology, 2020, 62, 89-96.	2.1	24
29	Losing a diagnosis of cerebral palsy: a comparison of variables at 2 and 5Âyears. Developmental Medicine and Child Neurology, 2020, 62, 83-88.	2.1	23
30	Cerebral palsy: Phenotypes and risk factors in term singletons born small for gestational age. European Journal of Paediatric Neurology, 2015, 19, 218-225.	1.6	22
31	Neonatal Infection in Children With Cerebral Palsy: A Registry-Based Cohort Study. Pediatric Neurology, 2018, 80, 77-83.	2.1	22
32	Behavioral difficulties, sleep problems, and nighttime pain in children with cerebral palsy. Research in Developmental Disabilities, 2019, 95, 103500.	2.2	21
33	The Association Between Maternal Age and Cerebral Palsy Risk Factors. Pediatric Neurology, 2018, 82, 25-28.	2.1	19
34	Familyâ€centred health care for children with cerebral palsy. Developmental Medicine and Child Neurology, 2019, 61, 62-68.	2.1	19
35	Current Practice and Views of Neurologists on the Transition From Pediatric to Adult Care. Journal of Child Neurology, 2012, 27, 1553-1558.	1.4	18
36	Cerebral palsy in Canada, 2011-2031: results of a microsimulation modelling study of epidemiological and cost impacts. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2020, 40, 25-37.	1.1	18

#	Article	IF	CITATIONS
37	Accuracy of administrative claims data for cerebral palsy diagnosis: a retrospective cohort study. CMAJ Open, 2017, 5, E570-E575.	2.4	17
38	Cerebral palsy after neonatal encephalopathy: do neonates with suspected asphyxia have worse outcomes?. Developmental Medicine and Child Neurology, 2016, 58, 189-194.	2.1	15
39	Profile of children with cerebral palsy spectrum disorder and a normal MRI study. Neurology, 2019, 93, e88-e96.	1.1	14
40	Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opinion on Investigational Drugs, 2021, 30, 519-527.	4.1	14
41	The Relationship Between Gross Motor Function and Manual Ability in Cerebral Palsy. Journal of Child Neurology, 2013, 28, 1646-1652.	1.4	13
42	Health-related quality of life in Canadian children with cerebral palsy: what role does sleep play?. Sleep Medicine, 2019, 54, 213-222.	1.6	13
43	Epilepsy in children with cerebral palsy: a data linkage study. Developmental Medicine and Child Neurology, 2022, 64, 259-265.	2.1	13
44	Interobserver Reliability for Identifying Specific Patterns of Placental Injury as Defined by the Amsterdam Classification. Archives of Pathology and Laboratory Medicine, 2022, 146, 372-378.	2.5	12
45	The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities. Paediatrics and Child Health, 2018, 23, 20-26.	0.6	11
46	Look Around Me: Environmental and Socio-Economic Factors Related to Community Participation for Children with Cerebral Palsy in Québec. Physical and Occupational Therapy in Pediatrics, 2021, 41, 1-18.	1.3	11
47	Term neonatal encephalopathy antecedent cerebral palsy: AÂretrospective population-based study. European Journal of Paediatric Neurology, 2013, 17, 269-273.	1.6	10
48	Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. Journal of Neuromuscular Diseases, 2021, 8, 543-551.	2.6	9
49	Perinatal arterial ischemic stroke and periventricular venous infarction in infants with unilateral cerebral palsy. Developmental Medicine and Child Neurology, 2021, , .	2.1	9
50	Current Referral Practices for Diagnosis and Intervention for Children withÂCerebral Palsy: A National Environmental Scan. Journal of Pediatrics, 2020, 216, 173-180.e1.	1.8	8
51	Validation of home portable monitoring for the diagnosis of sleep-disordered breathing in adolescents and adults with neuromuscular disorders. Journal of Clinical Sleep Medicine, 2021, 17, 1579-1590.	2.6	8
52	Profile of Pediatric Hemiparesis. Journal of Child Neurology, 2005, 20, 471-476.	1.4	7
53	Development and Validation of a Prediction Model for Perinatal Arterial Ischemic Stroke in Term Neonates. JAMA Network Open, 2022, 5, e2219203.	5.9	7
54	Use of consensus methods to determine the early clinical signs of cerebral palsy. Paediatrics and Child Health, 2020, 25, 300-307.	0.6	6

#	Article	IF	CITATIONS
55	A National Spinal Muscular Atrophy Registry for Real-World Evidence. Canadian Journal of Neurological Sciences, 2020, 47, 810-815.	0.5	6
56	Complementary and Alternative Therapy Use in Children with Cerebral Palsy. Canadian Journal of Neurological Sciences, 2021, 48, 408-414.	0.5	6
57	Perinatal Regionalization and Implications for Long-Term Health Outcomes in Cerebral Palsy. Canadian Journal of Neurological Sciences, 2016, 43, 248-253.	0.5	5
58	Cerebral palsy in Canadian Indigenous children. Developmental Medicine and Child Neurology, 2021, 63, 614-622.	2.1	5
59	Seizures in Epilepsy With Eyelid Myoclonia May Be Provoked by Eye Closure, Not Fixation Removal. Pediatric Neurology, 2020, 105, 62-64.	2.1	4
60	Prevalence and temporal trends of cerebral palsy in children born from 2002 to 2017 in Ontario, Canada: Populationâ€based cohort study. Developmental Medicine and Child Neurology, 2023, 65, 243-253.	2.1	4
61	Emergency Department Use in Children with Cerebral Palsy: A Data Linkage Study. Canadian Journal of Neurological Sciences, 2020, 48, 1-6.	0.5	3
62	Transient hyperreflexia. Neurology: Clinical Practice, 2020, 10, e66-e67.	1.6	3
63	Congenital Malformations in Children With Cerebral Palsy: Is Prematurity Protective?. Pediatric Neurology, 2020, 108, 70-76.	2.1	3
64	Hospitalizations in School-Aged Children with Cerebral Palsy and Population-Based Controls. Canadian Journal of Neurological Sciences, 2021, 48, 400-407.	0.5	3
65	Ataxic-hypotonic cerebral palsy in a cerebral palsy registry. Neurology: Clinical Practice, 2020, 10, 131-139.	1.6	3
66	Terminal 6p deletion syndrome mimicking CHARGE syndrome: A case report. Journal of Pediatric Genetics, 2015, 02, 103-107.	0.7	2
67	Disentangling racial and ethnic disparities in cerebral palsy. Developmental Medicine and Child Neurology, 2015, 57, 791-792.	2.1	2
68	Response to the Canadian Agency for Drugs and Technologies in Health and Institut national d'excellence en santé et en services sociaux decision regarding nusinersen for Spinal Muscular Atrophy. Canadian Journal of Neurological Sciences, 2018, 45, 516-517.	0.5	2
69	New Guidelines: Interpretation, Application and the Future. Headache, 2019, 59, 1133-1143.	3.9	2
70	Is Cerebral Palsy Changing in High Resource Settings? Data From the Quebec Cerebral Palsy Registry. Journal of Child Neurology, 2019, 34, 567-573.	1.4	2
71	A case report of Systemic Intoxication following Onabotulinum Toxin A Injections into the Salivary Glands in a patient with Spinal Muscular Atrophy Type 1. Pediatric Neurology, 2022, 129, 37-38.	2.1	1
72	Addressing heterogeneous needs using cerebral palsy registers. Developmental Medicine and Child Neurology, 2017, 59, 458-459.	2.1	0

#	Article	IF	CITATIONS
73	How socioâ€economic disadvantage modifies health outcomes in children with cerebral palsy. Developmental Medicine and Child Neurology, 2019, 61, 509-509.	2.1	0
74	Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective. Canadian Journal of Neurological Sciences, 2021, , 1-4.	0.5	0
75	Informing the development of the Canadian Neurodiversity Platform: What is important to parents of children with neurodevelopmental disabilities?. Child: Care, Health and Development, 2022, 48, 88-98.	1.7	0
76	Methodological challenges in measuring meaningful change in individuals with spinal muscular atrophy. Muscle and Nerve, 2021, 64, 639-640.	2.2	0
77	<i>NTRK1</i> -related Hereditary Sensory and Autonomic Neuropathy Type 4: The Role of the Histamine Challenge Test. Child Neurology Open, 2022, 9, 2329048X2211088.	1.1	0